MDPI and ACS Style
Zapolnik, P.; Kmiecik, W.; Nowakowska, A.; Krzych, Ł.J.; Szymański, H.; Stopyra, L.; Jackowska, T.; Darmochwał-Kolarz, D.; Mazur, A.; Czajka, H.
A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Phase III Clinical Trial Evaluating the Impact of BCG Re-Vaccination on the Incidence and Severity of SARS-CoV-2 Infections among Symptomatic Healthcare Professionals during the COVID-19 Pandemic in Poland—Evaluation of Antibody Concentrations. Vaccines 2023, 11, 75.
https://doi.org/10.3390/vaccines11010075
AMA Style
Zapolnik P, Kmiecik W, Nowakowska A, Krzych ŁJ, Szymański H, Stopyra L, Jackowska T, Darmochwał-Kolarz D, Mazur A, Czajka H.
A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Phase III Clinical Trial Evaluating the Impact of BCG Re-Vaccination on the Incidence and Severity of SARS-CoV-2 Infections among Symptomatic Healthcare Professionals during the COVID-19 Pandemic in Poland—Evaluation of Antibody Concentrations. Vaccines. 2023; 11(1):75.
https://doi.org/10.3390/vaccines11010075
Chicago/Turabian Style
Zapolnik, Paweł, Wojciech Kmiecik, Anna Nowakowska, Łukasz Jerzy Krzych, Henryk Szymański, Lidia Stopyra, Teresa Jackowska, Dorota Darmochwał-Kolarz, Artur Mazur, and Hanna Czajka.
2023. "A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Phase III Clinical Trial Evaluating the Impact of BCG Re-Vaccination on the Incidence and Severity of SARS-CoV-2 Infections among Symptomatic Healthcare Professionals during the COVID-19 Pandemic in Poland—Evaluation of Antibody Concentrations" Vaccines 11, no. 1: 75.
https://doi.org/10.3390/vaccines11010075
